Month: March 2023

Further to the announcement on February 6, 2023, Golar LNG Limited (“Golar”) is pleased to confirm today that the agreement to acquire New Fortress Energy Inc.’s (“NFE”) interest in FLNG Hilli, effective January 1, 2023, has closed.  In return for NFE’s 50% Common Unit holding in Golar Hilli LLC, Golar has transferred its remaining 4.1 million NFE shares to NFE, paid NFE $100 million in cash, and assumed approximately $323 million of FLNG Hilli debt. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur...

55% cost savings resulting from lower multiprotocol label switching (MPLS) usage and simpler administration Increased revenue and enhanced customer experience through 18x reduction in point of sale (POS) transaction time Improved operational efficiency through 4x increase in network speed and performance and the elimination of network downtimeSUNNYVALE, Calif., March 15, 2023 (GLOBE NEWSWIRE) — Fortinet® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today announced that Emirates National Oil Company Limited (ENOC), a wholly owned company of the Government of Dubai, has chosen Fortinet Secure SD-WAN to transform customer experience and increase operational efficiency. Established as a local oil and gas company in 1993, ENOC has grown to become a leading global player operating...

Reference is made to previous stock exchange announcements about delayed start up for the completed coastal cruise ship Havila Polaris. As reported earlier, the company has applied to Central Bank of Ireland for a license, which is crucial for the company to be able to pay off debts and to release the security linked to the vessels. The company is close to a solution but start up 7th of April is not possible with the timeframe presented. As a result, the company is forced to cancel another two roundtrips with Havila Polaris and the scheduled start-up of Havila Polaris is set for 29th April, and firmly believes this will be the last delay. The company once again strongly apologizes for the consequences for the passengers and locals along the coast. Contacts: CEO, Bent Martini: +47 905 99 650 CFO, Arne Johan Dale: +47 909 87 706  

SEATTLE, March 15, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced that the Company will present at the Sidoti Small-Cap Virtual Conference being held March 22-23, 2023. The presentation by Dr. Steven Quay, President and Chief Executive Officer and Kyle Guse, General Counsel and Chief Financial Officer, will take place on Thursday, March 23 at 1:00 pm eastern time. To register and view a live webcast of the presentation, please visit the event’s website at: https://sidoti.zoom.us/webinar/register/WN_Eeu2shzgQoOEjAkhs9zcng Following the conference, a recording of the webcast will be made available on the investor relations page of Atossa’s website: https://atossatherapeutics.com/investors ABOUT...

VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p

PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has been selected to present four posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting held from April 14 – 19, 2023 at Orange County Convention Center, Orlando, Florida. The available abstract titles and texts are based on previously-disclosed patient data. However, the posters presented at AACR will contain refreshed survival updates, new patient data, and potential late-breaking discoveries. Poster details include the following: Poster 1: Title: Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of...

Los Angeles, CA, March 15, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced details today of the remarkable experience of one of its Scientific Advisory Board Members, Dr. Gary Berns, while overseeing the rehabilitation treatments of Olympian and Surfing Champion Carlos Muñoz, following a devastating shoulder injury and subsequent accelerated recovery from highly invasive shoulder surgery utilizing Endonovo’s SofPulse® medical device. SofPulse® treatments applied to Muñoz’s surgically repaired shoulder resulted in significantly reduced recovery time, allowing Muñoz to re-enter the World Surf League (WSL) rankings and Championship Tour surfing competitions, nearly a year earlier than expected. Muñoz Career Prior To His Severe Shoulder Injury Carlos Muñoz is a Costa Rican surfer who rose to fame in 2008...